

## YUWIWEL - (1.3MG/VIAL, 2.8MG/VIAL, 5.5MG/VIAL; POWDER)

<b>Generic Name</b>	NAVEPEGRITIDE	<b>Innovator</b>	ASCENDIS PHARMA BONE
<b>Dosage</b>	1.3MG/VIAL, 2.8MG/VIAL, 5.5MG/VIAL; POWDER	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	YUWIWEL is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.